# Seronegative Myasthenia Gravis - Efgartigimod IV

> **NCT06587867** · PHASE3 · RECRUITING · sponsor: **University Health Network, Toronto** · enrollment: 30 (estimated)

## Conditions studied

- Efgartigimod
- Generalized Myasthenia Gravis

## Interventions

- **BIOLOGICAL:** efgartigimod

## Key facts

- **NCT ID:** NCT06587867
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-06-01
- **Primary completion:** 2025-05
- **Final completion:** 2025-05
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06587867

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06587867, "Seronegative Myasthenia Gravis - Efgartigimod IV". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06587867. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*